The US Food and Drug Administration (FDA) has granted approval to Indian pharmaceutical company Strides' wholly-owned subsidiary Shasun for its Acteazolamide tablets, the company said on Wednesday.
The US health regulator has approved Acteazolamide tablets to be used to prevent and reduce the symptoms of altitude sickness.
In a BSE filing, the company said that the product was a generic version of Diamox tablets.
It has been indicated in the dosages of 125 mg and 250 mg. Strides said the product, to be launched immediately, will be marketed by Strides Pharma Inc in the US.
According to IMS sales data, the US market for Acteazolamide tablets is worth approximately USD53m.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML